keyword
MENU ▼
Read by QxMD icon Read
search

Exenatide without diabetes

keyword
https://www.readbyqxmd.com/read/28454792/baseline-characteristics-of-patients-enrolled-in-the-exenatide-study-of-cardiovascular-event-lowering-exscel
#1
RANDOMIZED CONTROLLED TRIAL
Robert J Mentz, M Angelyn Bethel, Stephanie Gustavson, Vivian P Thompson, Neha J Pagidipati, John B Buse, Juliana C Chan, Nayyar Iqbal, Aldo P Maggioni, Steve P Marso, Peter Ohman, Neil Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F Hernandez, Rury R Holman
BACKGROUND: EXSCEL is a randomized, double-blind, placebo-controlled trial examining the effect of exenatide once-weekly (EQW) versus placebo on time to the primary composite outcome (cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) in patients with type 2 diabetes mellitus (DM) and a wide range of cardiovascular (CV) risk. METHODS: Patients were enrolled at 688 sites in 35 countries. We describe their baseline characteristics according to prior CV event status and compare patients with those enrolled in prior glucagon-like peptide-1 receptor agonist (GLP-1RA) outcomes trials...
May 2017: American Heart Journal
https://www.readbyqxmd.com/read/28452095/cost-effectiveness-of-exenatide-twice-daily-versus-insulin-glargine-as-add-on-therapy-to-oral-anti-diabetic-agents-in-type-2-diabetes-in-china
#2
Shuyan Gu, Xiaoyong Wang, Qing Qiao, Weiguo Gao, Jian Wang, Hengjin Dong
AIMS: This study aimed to estimate long-term cost-effectiveness of exenatide twice daily (EBID) versus insulin glargine once daily (IGQD) as add-on therapy to oral anti-diabetic agents (OADs) for Chinese patients with type 2 diabetes (T2DM). MATERIALS AND METHODS: Cardiff Diabetes Model was used to simulate disease progression and estimate long-term effects of EBID versus IGQD. Model-required patient profiles and treatment effects were obtained from literature reviews (English and Chinese databases) and meta-analysis of eight randomized clinical trials comparing EBID versus IGQD add-on to OADs for T2DM in China...
April 28, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28345814/dapagliflozin-once-daily-plus-exenatide-once-weekly-in-obese-adults-without-diabetes-sustained-reductions-in-bodyweight-glycaemia-and-blood-pressure-over-1-year
#3
Per Lundkvist, Maria J Pereira, Petros Katsogiannos, C David Sjöström, Eva Johnsson, Jan W Eriksson
AIMS: Dapagliflozin and exenatide reduce bodyweight by differing mechanisms. Dual therapy with these agents reduces bodyweight, adipose tissue volume, glycaemia, and systolic blood pressure (SBP) over 24 weeks. Here, we examined these effects over 1 year in obese adults without diabetes. MATERIALS AND METHODS: Obese adults without diabetes (N = 50; aged 18-70 years; body mass index 30-45 kg/m(2) ) initially randomized to double-blind oral dapagliflozin 10 mg once daily plus subcutaneous long-acting exenatide 2 mg once weekly or placebo entered an open-label extension from 24-52 weeks during which all participants received active treatment...
March 27, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28230449/real-world-glycemic-control-from-glp-1ra-therapy-with-and-without-concurrent-insulin-in-patients-with-type-2-diabetes
#4
Mukul Singhal, Sudhir Unni, Marisa Schauerhamer, Hiep Nguyen, Jeff Hurd, Carrie McAdam-Marx
BACKGROUND: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are recommended as add-on therapy in patients with uncontrolled type 2 diabetes (T2D), with no specific guidance as to timing versus insulin. Furthermore, real-world data assessing GLP-1RA outcomes with or without concurrent insulin therapy are lacking. OBJECTIVE: To identify glycemic response with GLP-1RAs by insulin use in patients with T2D at 1-year follow-up to inform decisions regarding GLP-1RA use with or without insulin...
March 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28210986/the-role-of-the-pharmacist-in-managing-type-2-diabetes-with-glucagon-like-peptide-1-receptor-agonists-as-add-on-therapy
#5
REVIEW
Jerry Meece
The prevalence and associated clinical burden of type 2 diabetes (T2D) is increasing in the USA and other countries. As a consequence, the role of the pharmacist in managing T2D is expanding, and it is becoming increasingly important for pharmacists to have a complete understanding of the disease course and treatment options. Pharmacists have a key role in the use of injectable therapies, including incretin-based treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs). This article discusses the role of the pharmacist in the management of patients with T2D, particularly with respect to the use of GLP-1RAs to achieve glycemic control...
February 16, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28029018/exenatide-versus-insulin-lispro-added-to-basal-insulin-in-a-subgroup-of-korean-patients-with-type-2-diabetes-mellitus
#6
Kun Ho Yoon, Elise Hardy, Jenny Han
BACKGROUND: The prevalence of type 2 diabetes mellitus (T2DM) and obesity is increasing in Korea. Clinical studies in patients with T2DM have shown that combining the glucagon-like peptide-1 receptor agonist exenatide twice daily with basal insulin is an effective glucose-lowering strategy. However, these studies were predominantly conducted in non-Asian populations. METHODS: We conducted a subgroup analysis of data from a multinational, 30-week, randomized, open-label trial to compare the effects of exenatide twice daily (n=10) or three times daily mealtime insulin lispro (n=13) among Korean patients with T2DM inadequately controlled (glycosylated hemoglobin [HbA1c] >7...
February 2017: Diabetes & Metabolism Journal
https://www.readbyqxmd.com/read/27899001/drug-interventions-for-the-treatment-of-obesity-in-children-and-adolescents
#7
REVIEW
Emma Mead, Greg Atkinson, Bernd Richter, Maria-Inti Metzendorf, Louise Baur, Nicholas Finer, Eva Corpeleijn, Claire O'Malley, Louisa J Ells
BACKGROUND: Child and adolescent obesity has increased globally, and can be associated with significant short- and long-term health consequences. OBJECTIVES: To assess the efficacy of drug interventions for the treatment of obesity in children and adolescents. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, PubMed (subsets not available on Ovid), LILACS as well as the trial registers ICTRP (WHO) and ClinicalTrials.gov. Searches were undertaken from inception to March 2016...
November 29, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27898183/effect-of-exenatide-on-postprandial-glucose-fluxes-lipolysis-and-%C3%A3-cell-function-in-non-diabetic-morbidly-obese-patients
#8
Stefania Camastra, Brenno Astiarraga, Andrea Tura, Silvia Frascerra, Demetrio Ciociaro, Andrea Mari, Amalia Gastaldelli, Ele Ferrannini
AIMS: To investigate the effect of exenatide on glucose disposal, insulin secretion, ß-cell function, lipolysis and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions. MATERIALS AND METHODS: Patients were assigned to exenatide 10 µg twice daily (EXE, n = 15) or control (CT, n = 15) for 3 months. Patients received a meal test/tracer study (MTT) to measure endogenous glucose production (EGP), rate of oral glucose appearance (RaO), insulin secretion rate (ISR), ß-cell function, hepatic insulin resistance (HIR) and adipose tissue insulin resistance (AT-IR) and insulin sensitivity (IS)...
March 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27669277/the-use-of-exenatide-in-managing-markers-of-cardiovascular-risk-in-patients-with-type-2-diabetes-a-systematic-review
#9
REVIEW
Omorogieva Ojo
OBJECTIVE: This review examines the use of exenatide twice daily in managing changes in markers of cardiovascular risk in patients with type 2 diabetes. BACKGROUND: Type 2 diabetes is a progressive metabolic disorder, which results from defects in insulin secretion and/or insulin action leading to chronic hyperglycaemia and associated cardiovascular complications. Despite the use of diet, exercise, oral antihyperglycaemic agents and insulin, the progressive nature of the condition means that the levels of the preventive and treatment measures would have to be increased and/or new therapies have to be developed in order to address the long term impact of type 2 diabetes...
September 23, 2016: International Journal of Environmental Research and Public Health
https://www.readbyqxmd.com/read/27550386/dapagliflozin-once-daily-and-exenatide-once-weekly-dual-therapy-a-24-week-randomized-placebo-controlled-phase-ii-study-examining-effects-on-body-weight-and-prediabetes-in-obese-adults-without-diabetes
#10
Per Lundkvist, C David Sjöström, Sam Amini, Maria J Pereira, Eva Johnsson, Jan W Eriksson
AIMS: To explore the effects of dual therapy with dapagliflozin and exenatide on body weight, body composition, glycaemic variables and systolic blood pressure (SBP) in obese adults without diabetes. MATERIALS AND METHODS: In this single-centre, double-blind trial, we randomized 50 obese adults without diabetes (aged 18-70 years; body mass index 30-45 kg/m(2) ) to oral dapagliflozin 10 mg once daily plus subcutaneous long-acting exenatide 2 mg once weekly or placebo...
January 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27531946/glucagon-like-peptide-1-glp-1-receptor-agonists-in-cardiac-disorders
#11
REVIEW
Jamie Wroge, Nancy Toedter Williams
OBJECTIVE: To evaluate the literature about the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the treatment of cardiac disorders, specifically myocardial infarction (MI) and heart failure (HF). DATA SOURCES: Searches were conducted in MEDLINE (1946-May 2016) and Excerpta Medica (1980-May 2016) using EMBASE with the search terms glucagon-like peptide 1, exenatide, albiglutide, liraglutide, dulaglutide, myocardial infarction, heart failure, and cardiovascular The references of relevant articles were reviewed to identify additional citations...
December 2016: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/27525540/efficacy-and-tolerability-of-exenatide-once-weekly-over-6-years-in-patients-with-type-2-diabetes-an-uncontrolled-open-label-extension-of-the-duration-1-study
#12
Robert R Henry, Eric J Klein, Jenny Han, Nayyar Iqbal
BACKGROUND: Long-term treatment is necessary to slow the progression of type 2 diabetes (T2D). Here, we examined the safety and efficacy of 6 years of treatment with exenatide once weekly (QW) among patients with T2D in the DURATION-1 trial. METHODS: The study enrolled patients aged ≥16 years with T2D treated primarily with metformin and sulfonylureas. Following 30 weeks of randomized treatment with exenatide QW 2 mg or exenatide twice daily 10 μg, patients entered an uncontrolled, open-label, open-ended study phase in which all patients received exenatide QW 2 mg...
November 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27485823/adjunctive-role-of-glucagon-like-peptide-1-receptor-agonists-in-the-management-of-type-1-diabetes-mellitus
#13
REVIEW
Kira B Harris, Cassie L Boland
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used in combination with insulin to manage type 2 diabetes mellitus, and four agents are currently approved for this indication: exenatide, liraglutide, dulaglutide, and albiglutide. The distinctive properties of GLP-1 RAs-potential hemoglobin A1c (A1C) reduction, weight loss, potential to reduce insulin doses, and lower hypoglycemia risk-have made these agents potential treatment options for patients with type 1 diabetes mellitus (T1DM) as well...
September 2016: Pharmacotherapy
https://www.readbyqxmd.com/read/27398720/exenatide-treatment-alone-improves-%C3%AE-cell-function-in-a-canine-model-of-pre-diabetes
#14
Viorica Ionut, Orison O Woolcott, Hasmik J Mkrtchyan, Darko Stefanovski, Morvarid Kabir, Malini S Iyer, Huiwen Liu, Ana V B Castro, Qiang Wu, Josiane L Broussard, Cathryn M Kolka, Isaac Asare-Bediako, Richard N Bergman
BACKGROUND: Exenatide's effects on glucose metabolism have been studied extensively in diabetes but not in pre-diabetes. OBJECTIVE: We examined the chronic effects of exenatide alone on glucose metabolism in pre-diabetic canines. DESIGN AND METHODS: After 10 weeks of high-fat diet (HFD), adult dogs received one injection of streptozotocin (STZ, 18.5 mg/kg). After induction of pre-diabetes, while maintained on HFD, animals were randomized to receive either exenatide (n = 7) or placebo (n = 7) for 12 weeks...
2016: PloS One
https://www.readbyqxmd.com/read/27343423/exenatide-in-obese-or-overweight-patients-without-diabetes-a-systematic-review-and-meta-analyses-of-randomized-controlled-trials
#15
Na Su, Yun Li, Ting Xu, Ling Li, Joey Sum-Wing Kwong, Heyue Du, Kaiun Ren, Qianrui Li, Jianshu Li, Xin Sun, Sheyu Li, Haoming Tian
BACKGROUND/OBJECTIVES: Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is increasingly used in obese or overweight patients with diabetes. However, its safety profile and effects on weight loss in non-diabetic obese or overweight population remain unclear. We aimed to evaluate efficacy and safety of exenatide in obese or overweight participants without diabetes. METHODS: We searched up to January 2016 in MEDLINE (Ovid SP), EMBASE (Ovid SP), Cochrane Central Register of Controlled Trials (CENTRAL), some Chinese databases and ClinicalTrials...
September 15, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27071367/effects-of-exenatide-on-weight-and-appetite-in-overweight-adolescents-and-young-adults-with-prader-willi-syndrome
#16
P Salehi, I Hsu, C G Azen, S D Mittelman, M E Geffner, D Jeandron
BACKGROUND: Prader-Willi syndrome (PWS) is associated with hyperphagia and hyperghrelinemia with major morbidity because of obesity without effective medical treatment targeting hyperphagia. Exenatide (Byetta [synthetic Exendin-4]; AstraZeneca, Wilmington DE) is a GLP-1 receptor agonist which reduces appetite and weight and may be an effective treatment in PWS. OBJECTIVE: The objective of this study is to determine the effect of a 6-month trial of exenatide on appetite, weight and gut hormones in youth with PWS...
June 2017: Pediatric Obesity
https://www.readbyqxmd.com/read/27027802/relationship-of-body-mass-index-with-efficacy-of-exenatide-twice-daily-added-to-insulin-glargine-in-patients-with-type-2-diabetes
#17
B H R Wolffenbuttel, L Van Gaal, S Durán-Garcia, J Han
This post hoc analysis assessed the evidence behind common reimbursement practices by evaluating the relationship of body mass index (BMI) ranges (<30, 30-35 and >35 kg/m(2) ) with treatment effects of exenatide twice daily among patients with type 2 diabetes. Patients received exenatide twice daily added to insulin glargine in two 30-week studies (exenatide twice daily vs insulin lispro, n = 627; exenatide twice daily vs placebo, n = 259). No association of baseline BMI with changes in efficacy variables was observed...
August 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/26998491/exenatide-treatment-causes-suppression-of-serum-ghrelin-levels-following-mixed-meal-test-in-obese-diabetic-women
#18
Figen Topyildiz, Sinem Kiyici, Zulfiye Gul, Deniz Sigirli, Metin Guclu, Gurcan Kisakol, Sinan Cavun
AIM: To investigate the effect of exenatide treatment on serum ghrelin levels in obese female patients with type 2 diabetes mellitus. METHODS: Fourteen female patients with type 2 diabetes mellitus being treated with metformin and exenatide were enrolled. A mixed meal test was applied to the patients while continuing with their daily medications. Blood samples were taken before and at 60, 120, and 180 minutes following mixed meal test to measure serum total ghrelin, glucose, and insulin levels...
2016: Journal of Diabetes Research
https://www.readbyqxmd.com/read/26864536/delivery-of-exenatide-and-insulin-using-mucoadhesive-intestinal-devices
#19
Vivek Gupta, Byeong-Hee Hwang, Nishit Doshi, Amrita Banerjee, Aaron C Anselmo, Samir Mitragotri
A major disadvantage associated with current diabetes therapy is dependence on injectables for long-term disease management. In addition to insulin, incretin hormone replacement therapies including exenatide have added a new class of drugs for Type-2 diabetes. Although efficacious, patient compliance with current diabetic therapy is poor due to requirement of injections, inability to cross the intestinal epithelium and instability in the gastrointestinal tract. Here, we report the efficacy of a mucoadhesive device in providing therapeutic concentrations of insulin and exenatide via oral administration...
June 2016: Annals of Biomedical Engineering
https://www.readbyqxmd.com/read/26803355/circulating-adiponectin-levels-in-type-2-diabetes-mellitus-patients-with-or-without-non-alcoholic-fatty-liver-disease-results-of-a-small-open-label-randomized-controlled-intervention-trial-in-a-subgroup-receiving-short-term-exenatide
#20
RANDOMIZED CONTROLLED TRIAL
Savvoula Savvidou, Kyparissia Karatzidou, Kalliopi Tsakiri, Asterios Gagalis, Prodromos Hytiroglou, John Goulis
AIM: Diabetes mellitus type 2 (DMT2) and non-alcoholic fatty liver disease (NAFLD) are both characterized by decreased circulating adiponectin. Recently, glucagon-like peptide-1 receptor agonists have been shown to induce adiponectin's expression. However, their interaction on clinical grounds needs to be further elucidated. METHODS: DMT2 patients with abnormal aminotransferases were screened for NAFLD and subjected to liver biopsy (group A, n=17). A subgroup of patients (n=110), after assessed for eligibility criteria, was blindly randomized to receive either 6-month exenatide supplementation on glargine insulin (group B) or intense, self-regulated, insulin therapy alone (group C)...
March 2016: Diabetes Research and Clinical Practice
keyword
keyword
110086
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"